Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
05 January 2023 - 08:01AM
Business Wire
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical
company developing engineered antibodies and cytokines for the
treatment of cancer and autoimmune diseases, today announced that
Bassil Dahiyat, Ph.D., president and chief executive officer, will
present at the 41st Annual J.P. Morgan Healthcare Conference on
January 11, 2023 at 3:45 p.m. PST.
A live webcast of the presentation will be available under
"Events & Presentations" in the Investors section of the
Company's website. A replay will be available for at least 30 days
following the presentation.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing
engineered antibodies and cytokines for the treatment of patients
with cancer and autoimmune diseases. More than 20 candidates
engineered with Xencor's XmAb® technology are in clinical
development, and three XmAb medicines are marketed by partners.
Xencor's XmAb engineering technology enables small changes to a
protein's structure that result in new mechanisms of therapeutic
action. For more information, please visit www.xencor.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230104005829/en/
Charles Liles cliles@xencor.com 626-737-8118
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Mar 2023 to Mar 2024